Vaxcyte (PCVX) Competitors $37.20 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$37.17 -0.03 (-0.08%) As of 04:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PCVX vs. ITCI, GMAB, SMMT, RDY, ASND, MRNA, VTRS, QGEN, BPMC, and ROIVShould you be buying Vaxcyte stock or one of its competitors? The main competitors of Vaxcyte include Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Moderna (MRNA), Viatris (VTRS), Qiagen (QGEN), Blueprint Medicines (BPMC), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry. Vaxcyte vs. Intra-Cellular Therapies Genmab A/S Summit Therapeutics Dr. Reddy's Laboratories Ascendis Pharma A/S Moderna Viatris Qiagen Blueprint Medicines Roivant Sciences Intra-Cellular Therapies (NASDAQ:ITCI) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, community ranking, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations. Do institutionals and insiders hold more shares of ITCI or PCVX? 92.3% of Intra-Cellular Therapies shares are owned by institutional investors. Comparatively, 96.8% of Vaxcyte shares are owned by institutional investors. 2.6% of Intra-Cellular Therapies shares are owned by company insiders. Comparatively, 3.1% of Vaxcyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media favor ITCI or PCVX? In the previous week, Vaxcyte had 3 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 3 mentions for Vaxcyte and 0 mentions for Intra-Cellular Therapies. Vaxcyte's average media sentiment score of 0.21 beat Intra-Cellular Therapies' score of 0.00 indicating that Vaxcyte is being referred to more favorably in the news media. Company Overall Sentiment Intra-Cellular Therapies Neutral Vaxcyte Neutral Does the MarketBeat Community favor ITCI or PCVX? Intra-Cellular Therapies received 467 more outperform votes than Vaxcyte when rated by MarketBeat users. However, 77.46% of users gave Vaxcyte an outperform vote while only 65.74% of users gave Intra-Cellular Therapies an outperform vote. CompanyUnderperformOutperformIntra-Cellular TherapiesOutperform Votes52265.74% Underperform Votes27234.26% VaxcyteOutperform Votes5577.46% Underperform Votes1622.54% Is ITCI or PCVX more profitable? Vaxcyte has a net margin of 0.00% compared to Intra-Cellular Therapies' net margin of -14.07%. Intra-Cellular Therapies' return on equity of -9.93% beat Vaxcyte's return on equity.Company Net Margins Return on Equity Return on Assets Intra-Cellular Therapies-14.07% -9.93% -8.38% Vaxcyte N/A -23.53%-22.20% Which has better valuation & earnings, ITCI or PCVX? Intra-Cellular Therapies has higher revenue and earnings than Vaxcyte. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntra-Cellular Therapies$680.50M20.64-$139.67M-$0.73-180.64VaxcyteN/AN/A-$402.27M-$3.99-9.27 Which has more risk and volatility, ITCI or PCVX? Intra-Cellular Therapies has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Comparatively, Vaxcyte has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Do analysts rate ITCI or PCVX? Intra-Cellular Therapies presently has a consensus price target of $109.70, suggesting a potential downside of 16.81%. Vaxcyte has a consensus price target of $136.50, suggesting a potential upside of 269.11%. Given Vaxcyte's stronger consensus rating and higher possible upside, analysts clearly believe Vaxcyte is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intra-Cellular Therapies 0 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17Vaxcyte 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10 SummaryVaxcyte beats Intra-Cellular Therapies on 12 of the 18 factors compared between the two stocks. Get Vaxcyte News Delivered to You Automatically Sign up to receive the latest news and ratings for PCVX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PCVX vs. The Competition Export to ExcelMetricVaxcyteBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.77B$3.12B$5.56B$8.64BDividend YieldN/A1.59%5.27%4.19%P/E Ratio-8.0433.6327.3020.18Price / SalesN/A488.11415.29164.91Price / CashN/A168.6838.2534.64Price / Book2.843.507.174.73Net Income-$402.27M-$72.35M$3.23B$248.08M7 Day Performance6.73%13.96%6.81%4.47%1 Month Performance18.68%28.03%15.59%10.83%1 Year Performance-48.55%-14.71%32.77%15.09% Vaxcyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PCVXVaxcyte2.3958 of 5 stars$37.20flat$136.50+266.9%-47.6%$4.80BN/A-8.09160Positive NewsGap UpITCIIntra-Cellular Therapies0.8914 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.2548 of 5 stars$21.77+3.9%$39.17+79.9%-19.9%$13.96B$3.12B12.511,660Positive NewsGap UpSMMTSummit Therapeutics2.9912 of 5 stars$17.73-2.7%$37.40+110.9%+179.3%$13.17B$700,000.00-63.32110Analyst RevisionGap UpHigh Trading VolumeRDYDr. Reddy's Laboratories1.2264 of 5 stars$14.73+0.0%$17.00+15.4%+9.6%$12.29B$325.54B23.4524,800ASNDAscendis Pharma A/S2.5589 of 5 stars$175.69+7.9%$216.07+23.0%+26.2%$10.71B$368.70M-24.75640Analyst ForecastAnalyst RevisionMRNAModerna4.4329 of 5 stars$27.05+1.8%$53.58+98.1%-81.4%$10.46B$3.14B-2.913,900VTRSViatris2.191 of 5 stars$8.69-1.1%$10.50+20.8%-15.9%$10.20B$14.33B-11.7437,000QGENQiagen3.1704 of 5 stars$44.89-0.5%$48.42+7.9%+5.9%$9.98B$2.00B125.006,030BPMCBlueprint Medicines0.9067 of 5 stars$127.79+26.1%$125.69-1.6%+23.8%$8.25B$562.12M-118.32640High Trading VolumeROIVRoivant Sciences2.3408 of 5 stars$11.17+1.6%$17.50+56.7%+5.8%$7.97B$29.05M-74.46860 Related Companies and Tools Related Companies Intra-Cellular Therapies Competitors Genmab A/S Competitors Summit Therapeutics Competitors Dr. Reddy's Laboratories Competitors Ascendis Pharma A/S Competitors Moderna Competitors Viatris Competitors Qiagen Competitors Blueprint Medicines Competitors Roivant Sciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PCVX) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredWhy 2026 will be a disaster for many Americans2025 Market Crash The first-quarter stock crash left investors wondering what lies ahead. Today 50-year Wal...Chaikin Analytics | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxcyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxcyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
